Skip to main content

Table 2 Baseline characteristics of the population on combination (AAB + AM)

From: Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia

Subjects

N = 191

Demographic characteristics

 Mean age, years

70.0 (10.4)

 Ranges: 45-64 years

29.8%

  65-74 years

33.5%

   ≥ 75 years

36.6%

 Pensioner

88.0%

General comorbidity

 Number of diagnoses

7.7 (4.2)

 Charlson Comorbidity Index

0.6 (0.7)

 RUB (morbidity)

3.0 (0.7)

  1 (very low)

4.7%

  2 (low)

10.1%

  3 (moderate)

69.2%

  4 (high)

15.4%

  5 (very high)

0.6%

Specific comorbidity

 Arterial hypertension

59.8%

 Dyslipidemia

51.3%

 Cardiovascular event

32.8%

 Diabetes mellitus

27.5%

 Active smoker

22.2%

 Vasculocerebral accident

22.2%

 Organ failures

19.6%

 COPD

18.5%

 Obesity

18.0%

 Ischemic heart disease

17.5%

 Depressive syndrome

14.8%

 Malignant neoplasms

13.2%

 Alcoholism

5.3%

 Asthma

4.8%

 Neuropathies

4.8%

 Dementias

2.6%

Clinical profile (symptoms)

 Storage

87.4%

 Voiding

47.6%

 Post-micturition

91.1%

Prostate volume (%)

 Volume I (<20 ml)

93.2%

 Volume II (>20-40 ml)

6.8%

 IPSS scale score

  Moderate symptoms (8-19 points)

71.2%

  Severe symptoms (20-35 points)

28.8%

Biochemical/anthropometric parameters

 Systolic blood pressure, mmHg

129.4 (15.0)

 Diastolic blood pressure, mmHg

72.5 (10.6)

 Body mass index kg/m2

29.0 (4.0)

 Total cholesterol, mg/dL

186.6 (42.1)

 Serum creatinine, mg/dL

1.1 (0.4)

 PSA (ng/mL)

0.9 (0.9)

  Low PSA (<1.5 g/L)

79.3%

  High PSA (≥1.5 g/L)

20.7%

  1. Values expressed as a percentage or mean (standard deviation)
  2. AAB alpha-blocker, AM antimuscarinic, COPD chronic obstructive pulmonary disease, IPSS international prostate symptom score, PSA prostate-specific antigen, RUB resource utilization bands